Podcasts about Diabetologia

Les hommes et les femmes ne sont pas égaux, mais ce n'est pas une question de société mais bel est bien de nature humaine. Comment gérer ces différences pour en faire une force ?

Ahead of Rare Disease Day on the 28th February, we speak with nutritionist, author and lifestyle medicine professional Rohini Bajekal about a rarer form of diabetes, MODY, or maturity onset diabetes of the young. Rohini shared the challenges she had to overcome to finally reach her diagnosis of this rare genetic condition.To connect with Rohini:www.rohinibajekal.comhttps://www.instagram.com/rohinibajekal Explanation of MODY: https://www.diabetesgenes.org/what-is-mody/ Guidelines for genetic testing in MODY: https://www.diabetesgenes.org/tests-for-diabetes-subtypes/guidelines-for-genetic-testing-in-mody/MODY calculator tool: https://www.diabetesgenes.org/exeter-diabetes-app/Genetic Test Referral Form: https://www.diabetesgenes.org/genetic-test-referral-forms/Diabetes UK information: https://www.diabetes.org.uk/about-diabetes/other-types-of-diabetes/modyExample case study: https://www.genomicseducation.hee.nhs.uk/genotes/in-the-clinic/presentation-patient-with-incidental-finding-of-raised-blood-glucose/Plant-Based Health Professionals UK Type 2 diabetes factsheet: https://plantbasedhealthprofessionals.com/wp-content/uploads/2024/11/Diabetes-factsheet08.11.24.pdf References Discussed:Chakera, A. J., Steele, A. M., Gloyn, A. L., Shepherd, M. H., Shields, B., Ellard, S., & Hattersley, A. T. (2015). Recognition and Management of Individuals With Hyperglycemia Because of a Heterozygous Glucokinase Mutation. Diabetes care, 38(7), 1383–1392. https://doi.org/10.2337/dc14-2769 https://pubmed.ncbi.nlm.nih.gov/26106223/Stride, A., Shields, B., Gill-Carey, O., Chakera, A. J., Colclough, K., Ellard, S., & Hattersley, A. T. (2014). Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia. Diabetologia, 57(1), 54–56. https://doi.org/10.1007/s00125-013-3075-x https://pubmed.ncbi.nlm.nih.gov/24092492/Steel AM, Shields BM, Wensley KJ and others. ‘Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia'. Journal of the American Medical Association 2014: volume 311, issue 3, pages 279–286. DOI: 10.1001/jama.2013.283980 https://jamanetwork.com/journals/jama/fullarticle/1814212

Are you or a loved one living with diabetes? Have you ever wondered if diabetes can truly be reversed, or if fruit is safe to eat on a diabetes-friendly diet? You're in the right place! In this episode, we sit down with Brenda Davis, world-renowned registered dietitian and leading expert in plant-based nutrition, to uncover the truth about diabetes and its reversal. Brenda shares groundbreaking insights into how a whole food, plant-based diet can dramatically improve health, lower blood sugar, and even reverse Type 2 diabetes.

Almost 2400 years ago, Hippocrates said "All disease begins in the gut"; and he was right. With modern scientific methods and studies to prove it, we can see exactly how and why all dieases begin in your gut, and what you can do to stop them. 93% od the leading causes of death are connected to your gut, and this episode is going to explain why that it, how it happens and to give you the tools you need to not only protect yourself and your loved ones, but even to reverse almost any diease.   TOPICS DISCUSSED: Reversing 93% of the leading causes of death The machanisms of how all diease begins in your gut How endotoxins (gut toxins) circulate around your body What they do to your organ systems and your body How to heal and seal your gut Reverse chronic inflammatory diseases How to heal from almost anything   Leave us a Review: https://www.reversablepod.com/review   Need help with your gut? Click the link, or visit gutsolution.ca for help: Get help now   Supplements: Get 15% off Practitioner Grade Supplements (forever) by creating an account   Contact us: reversablepod.com/tips    SOCIAL MEDIA: Instagram  Facebook  YouTube     STUDIES FOR REFERENCE: 1. LPS and Liver Disease: ·       Key Study: Lipopolysaccharides promote hepatic steatosis by activating the TLR4-NF-κB pathway in hepatocytes (Cai et al., 2012, Hepatology). Link: https://pubmed.ncbi.nlm.nih.gov/22025365/ 2. LPS and Kidney Disease: ·       Key Study: Role of lipopolysaccharide in the pathogenesis of kidney injury in sepsis (Matsushita et al., 2021, Nephrology). Link: https://pubmed.ncbi.nlm.nih.gov/33460487/ 3. LPS and Diabetes: ·       Key Study: Gut-derived endotoxin and metabolic inflammation in type 2 diabetes (Cani et al., 2007, Diabetologia). Link: https://pubmed.ncbi.nlm.nih.gov/17471239/ 4. LPS and Cancer: ·       Key Study: Gut microbiota-mediated inflammation in obesity: A link with gastrointestinal cancer (Cani et al., 2018, Nature Reviews Gastroenterology & Hepatology). Link: https://pubmed.ncbi.nlm.nih.gov/29348450/ 5. LPS and Cerebrovascular Disease: ·       Key Study: LPS-induced systemic inflammation exacerbates brain damage in ischemic stroke (Chen et al., 2016, Stroke). Link: https://pubmed.ncbi.nlm.nih.gov/26846899/ 6. LPS and Parkinson's Disease: ·       Key Study: Lipopolysaccharide induces neuroinflammation and dopaminergic neuron loss in Parkinson's disease models (Qin et al., 2007, Journal of Neuroscience). Link: https://pubmed.ncbi.nlm.nih.gov/17360907/ 7. LPS and Hypertension: ·       Key Study: Role of gut-derived endotoxemia in systemic inflammation and hypertension (Tang et al., 2017, Hypertension). Link: https://pubmed.ncbi.nlm.nih.gov/28209750/ 8. LPS and Colon/Gut Diseases: ·       Key Study: Lipopolysaccharides promote intestinal inflammation by disrupting the epithelial barrier (Schmidt et al., 2015, Gut). Link: https://pubmed.ncbi.nlm.nih.gov/25691570/ 9. Studies Supporting LPS's Role in Alzheimer's: ·       Study 1: Microbiome-derived lipopolysaccharide enriched in the perinuclear region of Alzheimer's disease brain (Zhao et al., 2017, Frontiers in Immunology). Link: https://pubmed.ncbi.nlm.nih.gov/28928740/ ·       Study 2: Lipopolysaccharides cause neuronal death and cognitive decline (Molecules, 2022). Link: https://pubmed.ncbi.nlm.nih.gov/35011994/ ·       Study 3: Neuroinflammation and Alzheimer's disease: Mechanisms of action (Nature Neuroscience, 2019). Link: https://pubmed.ncbi.nlm.nih.gov/30842661/

Settimo test di Starship: navicella incendiata e distrutta. Il commento di Roberto Battiston, fisico, già presidente dell’Agenzia Spaziale Italiana.Scavi a Pompei: emerge un grande complesso termale. Sentiamo Gabriel Zuchtriegel, direttore del Parco Archeologico di Pompei.Arriva anche in Italia Omnipod 5, un nuovo microinfusore per i pazienti con diabete di tipo 1 privo di catetere. Con noi Roberto Trevisan, professore di Endocrinologia presso l'Università Milano-Bicocca, direttore della Diabetologia dell'ASST Papa Giovanni XXIII di Bergamo.

Retrospectiva 2024: o principais destaques da diabetologia

Introducing Blood sugar hacks to give you more energy | Glucose Goddess Jessie Inchauspé and Prof. Tim Spector from ZOE Science & Nutrition.Follow the show: ZOE Science & Nutrition Why do some people feel fine eating lots of carbs when others feel energy slumps? Is blood sugar to blame?In this episode, we learn why blood sugar varies so much between people, and the tools to manage these levels. Tim Spector and Jessie Inchauspé (aka the Glucose Goddess) will discuss the latest science around glucose control, what the cool new device on the block – the CGM – can tell us and why blood sugar levels are only one part of the picture of our health.Jessie is a bestselling author and science communicator with a community of over 5 million followers. Tim is a professor of epidemiology at King's College London and ZOE's scientific co-founder.

In this episode, we discuss the efficacy and safety of semaglutide and tirzepatide for weight loss with a particular focus on the legal, regulatory, and safety aspects of these “compounded” GLP-1 receptor agonist medications. Key Concepts Semaglutide and tirzepatide have growing evidence that their clinical benefits extend beyond the treatment of diabetes. Evidence now shows benefit in a variety of obesity-related disease states regardless of a patient's diabetes status. Insurance coverage and drug cost is a major barrier to these medications, with cash prices exceeding $1000 per month in the US. There are many companies that are combining telemedicine visits with “compounded” GLP-1s to provide these medications at a reduced cost. The Food, Drug, and Cosmetic (FD&C) Act regulates compounded drugs. These regulations provide the legal context for pharmacies to compound GLP-1 medications. These regulations describe who can compound, what drugs can be compounded, and other unique circumstances (e.g. compounding in the context of a drug shortage). The FDA has released warnings regarding safety risks of compounded GLP-1s. The main safety concern is dosing errors; however, the warnings also include concerns of patients accessing drug products that are outside of the legal scope of the FD&C Act. The recent ADA statement recommends against the use of compounded GLP-1s due to these concerns. References Karagiannis T, Malandris K, Avgerinos I, et al. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia. 2024;67(7):1206-1222. doi:10.1007/s00125-024-06144-1 Müllertz ALO, Sandsdal RM, Jensen SBK, Torekov SS. Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety. Obes Rev. 2024;25(5):e13717. doi:10.1111/obr.13717 Jastreboff AM, Le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. New England Journal of Medicine. 2024. https://www.nejm.org/doi/full/10.1056/NEJMoa2410819 Contract Year 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly (CMS-4208-P). https://www.cms.gov/newsroom/fact-sheets/contract-year-2026-policy-and-technical-changes-medicare-advantage-program-medicare-prescription Human Drug Compounding. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/media/98973/download FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss Nomination of Semaglutide Products to the Demonstrable Difficulties for Compounding Lists. https://www.regulations.gov/document/FDA-2017-N-2562-0029 Neumiller JJ, Bajaj M, Bannuru RR, et al. Compounded GLP 1 and dual GIP/GLP 1 receptor agonists: A statement from the American Diabetes Association. Diabetes Care. 2024 Dec 2:dci240091. doi: 10.2337/dci24-0091.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: A push to change the defined stages of T1D, InsuJet is approved in Canada, new study linked T2D and dementia, new drug looked at to prevent hypoglycemia, big honors for a T1D author and more! Our interview with Clare Edge here.  Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:     Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX   The understanding of type 1 has changed a lot in the last 10-15 years, specifically with the definition of stages of the disease. Now some researchers suggest the current 2015 model is ready for another update. University of Florida Health diabetes researchers and collaborators last week issued a call to action in The Lancet Diabetes & Endocrinology, urging the development of a more precise method of calculating type 1 diabetes risk. Under the current staging system, this is Stage 1 of the disease, when a patient does not yet have elevated blood sugar but has two or more of these autoantibodies in the blood. Stage 2 is diagnosed when blood sugar begins to rise, indicating a dysfunctional pancreas in a patient who does not yet have clinical type 1 diabetes. That comes in Stage 3 with high blood sugar and, eventually, the classic symptoms of the disease, including frequent urination, weight loss and fatigue. Jacobsen, however, said the staging system requires more precision. This is especially important as the current staging model determines if a patient is eligible to receive a drug therapy called teplizumab, the only Food and Drug Administration-approved medication that can delay the onset of type 1 diabetes by an average of two years. The staging system, however, does not include a patient's age and these researchers say additional markers that would be important to consider include a greater array of abnormal metabolic measures beyond blood sugar and the presence of more autoantibodies.   https://www.gainesville.com/story/news/healthcare/2024/12/04/uf-health-scientists-propose-update-to-type-1-diabetes-staging-system/76734459007/ XX A product called InsuJet gets approval in Canada. Made by NuGen Medical Devices, InsuJet™ is a needle-free injection system. It's already approved for sale in 42 countries – not yet the US. Their website says InsuJet's jet-injected fluid penetrates the skin through a small orifice of a special nozzle, creating a thin, high pressure stream. This way, insulin doesn't remain around the place of injection, like it does with a needle. Instead, with InsuJet, the insulin is deposited into the subcutaneous tissue where it's easily absorbed and acts faster– saving you money, time, and discomfort.   https://finance.yahoo.com/news/nugen-announces-canada-wide-launch-221500674.html XX Individuals diagnosed with type 2 diabetes before the age of 50 may be at a higher risk of developing dementia later in life. A study led by researchers at NYU Rory Meyers College of Nursing, says the risk is notably greater among adults with obesity. Type 2 diabetes is a known risk factor for dementia. Although the underlying mechanisms are not fully understood, scientists think that some of the hallmarks of diabetes—such as high blood sugar, insulin resistance, and inflammation—may encourage the development of dementia in the brain.     The researchers note that this greater understanding of the connection between diabetes onset, obesity, and dementia may help inform targeted interventions to prevent dementia. https://scitechdaily.com/diagnosed-young-with-diabetes-your-dementia-risk-may-be-higher/ XX Embecta is out of the insulin patch pump business – just months after getting the ok from the FDA. Embecta received FDA clearance for its insulin patch pump in September. The device is indicated for people with Type 1 or Type 2 diabetes and includes a 300-unit insulin reservoir to support people with higher daily insulin needs. However, the version Embecta received clearance for was an open-loop patch pump, where users manually control insulin delivery, while the firm's goal was to develop a closed-loop version, which automatically delivers insulin when needed. The CEO also expects competition in closed-loop devices for people with Type 2 diabetes to intensify, with Insulet receiving FDA clearance for its Omnipod 5 patch pump for Type 2 diabetes in August. https://www.medtechdive.com/news/embecta-discontinue-patch-pump/734059/ XX Sanofi invests in a company developing a new drug to prevent hypoglycemia. We reported on Zucara Therapeutics back in 2022 and they've been moving ahead with ZT-01. ZT-01 is a medication being developed to help prevent dangerous low blood sugar (hypoglycemia) by fixing how the body normally fights it. In people without diabetes, a hormone called glucagon is released to raise blood sugar when it gets too low. But in people with insulin-dependent diabetes, like type 1 diabetes or some forms of type 2 diabetes, this process doesn't work well because another hormone, somatostatin (SST), blocks glucagon from being released. ZT-01 works by blocking the effects of somatostatin, allowing the body to release more glucagon when it's needed. This could help people with diabetes avoid severe low blood sugar episodes.   https://www.prnewswire.com/news-releases/zucara-therapeutics-announces-strategic-investment-from-sanofi-as-part-of-us20-million-series-b-financing-302301820.html XX Omnipod 5 is now compatible with the FreeStyle Libre 2 plus. The company says the recent development “ makes Omnipod 5 the most connected tubeless AID system in the U.S.” It's already compatible with Dexcom's G6 and G7 CGMs. https://www.businesswire.com/news/home/20241120268759/en/Insulet-Announces-Omnipod%C2%AE-5-System-is-Now-Compatible-with-Abbott%E2%80%99s-FreeStyle-Libre-2-Plus-Sensor-in-the-U.S. XX A new study involving 11 clinical centers across the United States aims to uncover how type 1 diabetes (T1D) impacts brain health and cognitive function in children. Led by the Keck School of Medicine of the University of Southern California, this is a five-year study to explore critical questions about how environmental, lifestyle, social and clinical factors affect brain development during childhood — a period crucial for cognitive growth. https://www.managedhealthcareexecutive.com/view/new-study-to-explore-impact-of-type-1-diabetes-on-children-s-brain-development XX Dexcom looking to partner with smart ring company Oura. Originally launched to track sleep patterns, the latest Oura technology collects more than 20 biometrics ranging from heart rate and activity metrics to sleep and body temperature monitoring. The companies say the new partnership is intended to provide users with seamless integration between the two ecosystems so shared users can track their glucose levels and understand the impact of behaviors and biology on their metabolic health. https://www.forbes.com/sites/saibala/2024/11/29/smart-ring-maker-oura-hits-5-billion-in-valuation--strikes-major-partnership-with-dexcom/ XX   WEDNESDAY, Dec. 4, 2024 (HealthDay News) -- Taking even high doses of supplementary vitamin D won't lower an older person's odds for type 2 diabetes, new research confirms. They published their findings Dec. 2 in the journal Diabetologia. The new research followed on data from other studies that had suggested that people with especially low levels of vitamin D might face a higher risk for diabetes. That was true for people who were already prediabetic, especially. To find out, researchers led by Jirki Vyrtanen, from the University of Eastern Finland, randomly assigned nearly 2,300 people aged 60 or older to receive either placebo pills or 40 or 80 micrograms of vitamin D3 supplements per day, for five years.  At the end of the five years, "105 participants developed type 2 diabetes: 38 in the placebo group, 31 in the group receiving 40 micrograms of vitamin D3 per day, and 36 in the group receiving 80 micrograms of vitamin D3 per day," according to a university news release. In other words, there were no significant differences in the rate at which people developed type 2 diabetes, regardless of how much supplemental vitamin D they took. Vytanen's team also saw no benefit from high-dose supplements on a person's blood sugar or insulin levels, or measures of overweight/obesity. The bottom line, according to the researchers: For any healthy, non-prediabetic person with healthy vitamin D levels, upping intake of the vitamin won't alter your odds for diabetes or its common risk factors. https://www.usnews.com/news/health-news/articles/2024-12-04/high-dose-vitamin-d-supplements-wont-prevent-diabetes-in-healthy-seniors XX Big congrats to author Clare Edge – recent guest on the podcast. Her book, Accidental Demons is featured on People Magazine's top ten book gift suggestions for this year! Whether you're looking for books about winter and the holidays, a primer on some of this year's buzziest musicians and characters or that "one more chapter" kind of bedtime favorite, there's sure to be a book out there to suit their taste. Bernadette Crowley, also known as Ber, comes from a long line of witches. When Ber is diagnosed with diabetes, however, she learns that every time she tests her blood sugar, demons accidentally slip into the human dimension — and it's up to Ber and her sister, Maeve, to stop them. This fantastical book is a great escape for young readers over holiday break. Buy Now Top ten books https://people.com/kids-gift-book-suggestions-wicked-taylor-swift-books-8752097

ROMA (ITALPRESS) - Rafforzare il dialogo e la collaborazione tra istituzioni, comunità scientifica e centri ospedalieri. Con questo obiettivo è nato l'Intergruppo Parlamentare Endocrinologia e Diabetologia Pediatrica. Presieduto dalla senatrice Elena Murelli, membro della 10a Commissione, e co-presieduto dal deputato Luca Toccalini, l'Intergruppo è supportato scientificamente da Valentino Cherubini, Presidente della Società Italiana di Endocrinologia e Diabetologia Pediatrica e a guida del Comitato degli esperti. L'Italia ha assunto un ruolo di leadership mondiale attraverso l'approvazione unanime della Legge 130/2023, prima a introdurre uno screening pediatrico nazionale per la diagnosi precoce del diabete di tipo 1 e della celiachia. Composto da specialisti del settore, il Comitato offre supporto tecnico-scientifico per sostenere l'elaborazione di proposte legislative e identificare priorità di intervento nell'interesse dei pazienti pediatrici.f04/mgg/mrv/gsl

ROMA (ITALPRESS) - Rafforzare il dialogo e la collaborazione tra istituzioni, comunità scientifica e centri ospedalieri. Con questo obiettivo è nato l'Intergruppo Parlamentare Endocrinologia e Diabetologia Pediatrica. Presieduto dalla senatrice Elena Murelli, membro della 10a Commissione, e co-presieduto dal deputato Luca Toccalini, l'Intergruppo è supportato scientificamente da Valentino Cherubini, Presidente della Società Italiana di Endocrinologia e Diabetologia Pediatrica e a guida del Comitato degli esperti. L'Italia ha assunto un ruolo di leadership mondiale attraverso l'approvazione unanime della Legge 130/2023, prima a introdurre uno screening pediatrico nazionale per la diagnosi precoce del diabete di tipo 1 e della celiachia. Composto da specialisti del settore, il Comitato offre supporto tecnico-scientifico per sostenere l'elaborazione di proposte legislative e identificare priorità di intervento nell'interesse dei pazienti pediatrici.f04/mgg/mrv/gsl

Sensori per la glicemia e microinfusori di insulina hanno rivoluzionato la qualità di vita dei giovani con diabete di tipo 1. Ma negli ultimi tempi, sempre più spesso, ne stanno beneficiando anche gli adulti-anziani con diabete di tipo 2 in trattamento insulinico. A Obiettivo Salute il commento del prof. Dario Pitocco, associato di Endocrinologia all'Università Cattolica del Sacro Cuore e Direttore della UOSA di Diabetologia della Fondazione Policlinico Gemelli IRCCS, che con il suo gruppo ha pubblicato recentemente su Diabetes, Obesity and Metabolism una ricerca proprio su questo tema sottolineando come la tecnologia oggi permetta di mantenere stabili i valori di glicemia

Maltempo: esonda il Lamone a Traversara di Bagnacavallo. Ci colleghiamo con Francesco Ravagli, assessore ai lavori pubblici del Comune di Bagnacavallo. Prendendo spunto dal guasto di martedì e dalla morte di un operaio travolto da un Intercity a Bologna, ragioniamo sullo stato della sicurezza e dei controlli in ambito ferroviario con Paolo Beria, docente di economia e pianificazione dei trasporti del Politecnico di Milano. Una donna diabetica riesce ora a produrre insulina in seguito ad un trapianto di staminali. Ne parliamo con Roberto Trevisan, professore di Endocrinologia presso l'Università Milano-Bicocca, direttore della Diabetologia dell'ASST Papa Giovanni XXIII di Bergamo.

Diabete di tipo 2: aumentano i casi tra i giovanissimi. Questi i risultati di uno studio osservazionale su scala globale in corso di pubblicazione sulla rivista Diabetologia coordinato dall’Azienda Ospedaliero-Universitaria delle Marche e dall’Università Politecnica delle Marche che commentiamo a Obiettivo Salute con Valentino Cherubini, presidente SIEDP (Società Italiana di Endocrinologia e Diabetologia pediatrica) e Direttore della Diabetologia Pediatrica degli Ospedali Riuniti di Ancona.

We've been hearing a lot more about screening for type 1 diabetes – I saw my first mainstream commercial for it last week – but what does that mean? If you have type 1 or you have a child with T1D, are you thinking about screening other family members? Should you? Over the summer new guidelines were announced for health care providers – including mental health guidelines. There's a lot to unpack here.. my guest is the director of community screening and clinical trials education with BT1D. My guest this week is Anastasia Albanese-O'Neill, the director of community screening and clinical trials education with BT1D. As you'll hear, her daughter was diagnosed in 2002.. and Anastasia transitioned to a career in diabetes education and research a few years later. This summer, Breakthrough T1D led an effort to develop the first internationally agreed-upon guidance for anyone who tests positive for T1D autoantibodies, co-published today in the journals Diabetes Care and Diabetologia.   This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.

Why do some people feel fine eating lots of carbs when others feel energy slumps? Is blood sugar to blame? In this episode, we learn why blood sugar varies so much between people, and the tools to manage these levels.  Tim Spector and Jessie Inchauspé (aka the Glucose Goddess) will discuss the latest science around glucose control, what the cool new device on the block – the CGM – can tell us and why blood sugar levels are only one part of the picture of our health. Jessie is a bestselling author and science communicator with a community of over 5 million followers. Tim is a professor of epidemiology at King's College London and ZOE's scientific co-founder.

Less than a month after rebranding from JDRF to Breakthrough T1D, the leading type 1 diabetes advocacy organization has now released new consensus guidance related to the monitoring of early-stage type 1 diabetes. Debuted on the final day of the 84th American Diabetes Association Scientific Sessions, the consensus document seeks to fill a gap in guidance around autoantibody-positive individuals in early-stage type 1 diabetes as the community develops new means to delay or prevent progression of the disease. Proof of the document's significance, it has received endorsement from both the ADA and the European Association for the Study of Diabetes, with simultaneous publication in Diabetes Care and Diabetologia. “We are experiencing a paradigm shift in type 1 diabetes care, and we can now identify people in the earlier, presymptomatic stages of type 1 diabetes, before insulin is required, and intervene,” said Anastasia Albanese-O'Neill, PhD, APRN, associate vice president of Breakthrough T1D. “Until now, there was no consensus on how to care for these individuals in the clinical setting and provide appropriate education and psychological support. This new guidance should be used widely by healthcare providers to inform and guide the care of individuals in early stage T1D.” Presented in a special symposium dedicated to the new consensus guidance, the document clocks in at 29 pages in length and cites more than 170 references. Included within the guidance are specific sections dedicated to monitoring among children and adolescents, adult patients, and pregnant patients. Beyond guidance on monitoring, the document also dedicates space to outlining updated terminology on type 1 diabetes staging and how to provide psychosocial and educational support for affected individuals and families. To learn more about this new guidance and discuss the future of type 1 diabetes, hosts of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, Diana Isaacs, PharmD, and Natalie Bellini, DNP, sat down with Albanese-O'Neill at ADA 2024. During their conversation, hosts discuss the recent name change to Breakthrough T1D, the growing prevalence of adults being diagnosed with type 1 diabetes, and major takeaways from the consensus guidance.

It's In the News! A look at the top diabetes stories and headlines happening now. Top stories this week: The Eversense CGM could soon be approved for one year of continuous use, the first generic GLP-1 medication is launched, a new company tauts and all-in-one sensor and pump infusion set, a new diabetes accessory in the Roblox game, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom  Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX In the news is brought to you by Edgepark simplify your diabetes journey with Edgepark XX The first ever generic GLP-1 medication will soon be available in the US. It's a generic of Victoza, originally approved by the FDA in 2010 for diabetes, is part of the same class of drugs that includes Ozempic and Mounjaro. Liraglutide is Glucagon-like peptide-1 receptor agonists (otherwise known as GLP-1s or GLP-1 RAs) are a class of incretin drugs that mimic the body's natural hormones to help treat diabetes and obesity. However, the popularity of the drugs has spiraled out of control at times, leading to shortages and supply chain issues in the US and abroad.  The arrival of a GLP-1 generic drug provides reasons to be hopeful for doctors and patients alike, but there are also caveats. Couple of caveats - liraglutide is injected once daily (vs. weekly) and many doctors say it doesn't work as well for as many people as semaglutide and terzepatide. No confirmation on the price Two other generic options are being developed and could launch in December 2024. Patents for newer GLP-1 medications like Ozempic and Wegovy won't expire until several years down the road https://www.healthline.com/health-news/victoza-generic-glp1-drug-available XX Senseonics plans to launch a 365-day sensor in the U.S. in the fourth quarter of this year. A one-year Eversense CGM could be a game changer for the company.   In 2024, Senseonics expects to more than double U.S. new patient starts and increase the global installed base by around 50%. The growth is built on the current 180-day version of Senseonics' implantable Eversense CGM. Eversense's 180-day sensor can need calibrating twice a day, something Senseonics CEO Tim Goodnow said “has been a competitive disadvantage.” Users calibrate the 365-day sensor once a week. Senseonics is in talks with insulin pump manufacturers about integrating its Eversense CGM with their devices but has yet to commit to a timeline for finalizing an agreement. https://www.medtechdive.com/news/senseonics-365-day-cgm-2025-sales/719717/ XX People who take Ozempic or Wegovy may have a higher risk of developing a rare form of blindness, a new study suggests. Still, doctors say it shouldn't deter patients from using the medicines to treat diabetes or obesity.   Last summer, doctors at Mass Eye and Ear noticed an unusually high number of patients with non-arteritic anterior ischemic optic neuropathy, or NAION, a type of eye stroke that causes sudden, painless vision loss in one eye.   The condition is relatively rare — up to 10 out of 100,000 people in the general population may experience it — but the doctors noted three cases in one week, and each of those patients was taking semaglutide medications. The risk was found to be greatest within the first year of receiving a prescription for semaglutide.   The study, published Wednesday in the medical journal JAMA Ophthalmology, cannot prove that semaglutide medications cause NAION. And the small number of patients — an average of about 100 cases were identified each year — from one specialized medical center may not apply to a broader population. The ways that semaglutides interact with the eyes are not entirely understood. And the exact cause of NAION is not known either. The condition causes damage to the optic nerve, but there is often no warning before vision loss.   For now, patients who are taking semaglutide or considering treatment should discuss the risks and benefits with their doctors, especially those who have other known optic nerve problems such as glaucoma or preexisting visual loss, experts say https://www.reuters.com/business/healthcare-pharmaceuticals/wegovy-ozempic-linked-with-sight-threatening-eye-disorder-study-2024-07-03/ XX We got some updates at ADA about the over the counter CGMS Dexcom Stelo and Abbot's Libre. Dexom plans a late august launch of stelo, which you'll order from their website – it won't be physically in stores. Abbott also plans to sell its wellness-oriented Lingo device this summer through an e-commerce website. That's a sensor that's been available in other coutnires for a while, but was recently okayed in the US. It's not meant for people with diabetes. The Libre Rio is designed or adulst with type 2 who don't use insulin. No timing yet on that product's launch. Neither Abbott nor Dexcom have disclosed pricing for the upcoming products. https://www.medtechdive.com/news/abbott-dexcom-over-the-counter-cgm-launch/719928/ XX Insulet is looking to expand the label for its Omnipod 5 insulin pump for people with Type 2 diabetes. The company said Friday it recently filed with the Food and Drug Administration. Insulet presented study results at the American Diabetes Association's 84th Scientific Sessions that evaluated Omnipod 5 in people with Type 2 diabetes who were taking basal insulin or multiple daily injections. The results showed “substantial improvements in blood glucose outcomes and overall quality of life,” said study chair Francisco Pasquel, an associate professor of endocrinology at Emory School of Medicine. Omnipod 5 is currently cleared in the U.S. for people with Type 1 diabetes. Insulet hopes to expand the pump to people with Type 2 diabetes, with an expected launch in early 2025. The FDA has not yet cleared any automated insulin delivery systems for people with Type 2 diabetes, Insulet said. The company has a basal-only insulin pump, called Omnipod Go, that was cleared for people with Type 2 diabetes last year, but it does not connect to other devices. Even though Omnipod 5 is not currently indicated for Type 2 diabetes, doctors prescribe it for their patients with full reimbursement since the pharmacy channel doesn't distinguish between Type 1 or Type 2 patients, J.P. Morgan analyst Robbie Marcus wrote in a research note on Sunday. https://www.medtechdive.com/news/insulet-omnipod-5-type-2-diabetes-study/719644/ XX In the keynote address at the American Diabetes Association annual conference, FDA Commissioner Dr. Robert Califf expressed concerns about the rising rates of diabetes in the U.S. Though revolutionary medications and technologies for diabetes and weight loss continue to emerge, these treatments are vastly underused. The silver lining lies with type 1 diabetes therapies, which are showing great promise in clinical trials. “For the larger epidemic of type 2 diabetes, we're failing right now,” Califf said. “I don't say that lightly.” A huge problem, Califf said, is access. While most health insurance plans cover medical devices and medications for diabetes, without insurance, costs add up quickly. Ozempic, for example, costs nearly $1,000 per month without insurance. Studies have found that regardless of insurance status, roughly 26% of Americans skipped or delayed treatment due to cost. https://diatribe.org/diabetes-management/fda-commissioner-says-were-failing-people-type-2-diabetes XX Embecta presented two abstracts at the American Diabetes Association Scientific Sessions last weekend making the case for its insulin patch pump for Type 2 diabetes. The company submitted the device for Food and Drug Administration clearance in late 2023. The diabetes device company developed a patch pump with a larger insulin reservoir that can hold up to 300 units. Embecta, which is better known for making equipment such as pen needles and insulin syringes, has been developing its first patch pump. The company found that a device with a larger insulin reservoir could provide longer wear times and fewer disposable patches. https://www.medtechdive.com/news/embecta-insulin-patch-pump-volume-american-diabetes-association/719779/ XX   Pump/CGM sensor in one The niaa signature patch pump, shown with a watch displaying current blood sugar level The niaa signature patch pump has a manual bolus button and is part of an in-development AID system. Swiss technology maker Pharmasens demonstrated a new semi-reusable tubeless patch pump and glucose sensor in the same compact device, called the niia signature, which the company says can be worn for five days.   The top of the device, which includes Bluetooth connectivity and the electronic and mechanical parts to control the pump, separates from the disposable 300-unit reservoir along with the adhesive used to attach the device to the body via a steel cannula. A small button on the device allows manual bolusing. The company says an AID system will manage the device, controlled by smartphone.   PharmaSens' simpler basal-bolus patch pump, the niia essential, was submitted for FDA approval in late December. Availability of the niia signature AID system has yet to be announced. https://diatribe.org/diabetes-technology/diabetes-technology-display-ada-2024 XX Edgepark Commercial XX New international consensus statement offers guidance on the care and monitoring of people who are at high risk for type 1 diabetes (T1D). This is all about screening and testing for islet autoantibodies. These individuals are classified as: At risk or Stage 0 (single autoantibody or transient single autoantibody), Stage 1 (two or more autoantibodies with normoglycemia), and Stage 2 (two or more autoantibodies with dysglycemia but without symptoms and not yet meeting diagnostic criteria for Stage 3 clinical T1D). The document was presented on June 24, 2024 in a 90-minute symposium at the American Diabetes Association's annual Scientific Sessions and published simultaneously in both Diabetes Care and Diabetologia. "This is not guidance around who to screen or when to screen. This is guidance for the hundreds of thousands of people around the world who have participated in screening, mostly through research programs, and have been identified with positive autoantibodies and need care in the clinical setting," panel co-chair Anastasia Albanese-O'Neill, PhD, APRN, CDCES, of Breakthrough T1D, told Medscape Medical News.   The recommendations also include when to start insulin, and how to provide education and psychosocial support to individuals and family members of those given the early-stage T1D diagnosis. https://www.medscape.com/viewarticle/experts-advise-early-risk-monitoring-type-1-diabetes-2024a1000bpo XX Roblox has added a diabetic option, complete with insuli pen and Dexcom You can find it in the marketplace JDRF – now breakthrough t1d – started a world in roblox a couple of years ago as well Roblox is a super popular online game that a lot of kids play. https://www.roblox.com/games/5823990610/Breakthrough-T1D-World XX FFL next week! Join us again soon!

ROMA (ITALPRESS) - La tiroide è una piccola ghiandola a forma di farfalla posta alla base del collo, che controlla molte funzioni dell'organismo attraverso la produzione degli ormoni T3 e T4. Gli ormoni tiroidei regolano la respirazione, il battito cardiaco, la temperatura corporea, lo sviluppo del sistema nervoso centrale e la crescita corporea. Quanto la tiroide produce troppi ormoni si parla di ipertiroidismo, con sintomi quali nervosismo, ansia, iperattività, perdita di peso, battito cardiaco rapido o irregolare. Al contrario, se la tiroide non produce abbastanza ormoni, si verifica l'ipotiroidismo, che può causare obesità, dolori articolari, infertilità e malattie cardiache. Secondo le stime attuali, in Italia le persone che soffrono di patologie della tiroide sono più di 6 milioni, in prevalenza donne. Sono questi alcuni dei temi trattati da Andrea Lania, responsabile dell'unità operativa di endocrinologia e diabetologia dell'Istituto Humanitas di Rozzano, professore ordinario di endocrinologia e direttore della scuola di specializzazione di endocrinologia e malattie del metabolismo di Humanitas University, intervistato da Marco Klinger, per Medicina Top, format tv dell'agenzia di stampa Italpress.fsc/gsl

MILANO (ITALPRESS) - Patologie della tiroide, medicina estetica e le posizioni manageriali calcistiche a contatto con infortuni e difficoltà: sono i temi della trentaseiesima puntata di Medicina Top. Marco Klinger intervista Andrea Lania, Responsabile dell'Unità Operativa di Endocrinologia e Diabetologia dell'Humanitas di Rozzano; Maurizio Cavallini, specialista in chirurgia estetica; Ivan Cordoba, ex calciatore e ora dirigente sportivo.fsc/gsl

L’Agenzia Europea del Farmaco approva la prima insulina settimanale al mondo per il trattamento dei pazienti adulti con diabete. Ne parliamo a Obiettivo Salute con la prof.ssa Raffaella Buzzetti, presidente eletto della Società Italiana di Diabetologia.

ROMA (ITALPRESS) - “Un'alleanza internazionale per vincere il diabete” è l'evento che si è svolto questa mattina a Palazzo Wedekind, a Roma, aperto dal messaggio di saluto del Ministro della Salute Orazio Schillaci, con l'obiettivo di discutere di screening per il diabete di tipo 1, prospettive di impegno internazionale e dell'importanza di migliorare la qualità di vita dei pazienti. L'evento - realizzato con il contributo non condizionante di Sanofi, Revvity e Movi, patrocinato da Farmindustria, Federazione Italiana Medici Pediatri, Società Italiana di Diabetologia, Associazione Medici Diabetologi e Società Italiana di Endocrinologia e Diabetologia Pediatrica - ha visto la partecipazione attiva di Fondazione Italiana Diabete e Diabete Italia Onlus.f04/fsc/gtr

di Irene Barrese e Giulia Mengolini Una produzione realizzata con il supporto non condizionante di Medtronic |Quando parliamo di ricerca, pensiamo a laboratori asettici, a enormi microscopi e provette sterili, a ricercatori in camice persi nei loro numeri. La ricerca invece è fatta di persone e per le persone; e nel caso del diabete, patologia in cui il paziente è chiamato a prendere da solo tutte le decisioni terapeutiche, è più che mai necessario che queste due parti, il ricercatore e il paziente, imparino a collaborare e aiutarsi a vicenda. Ne parliamo con Francesca Ulivi, direttrice della Fondazione italiana diabete, e Manuela Battaglia, Managing Director di Innodia. Con una dedica speciale, e un'appendice in cui alcuni amici funamboli ci raccontano la prima cosa che faranno quando qualcuno finalmente dirà: abbiamo una cura. Perché quel giorno, verrà. 

Il nuovo protocollo, già sperimentato con successo all'ospedale San Bassiano nella stessa Ulss 7, permetterà di agevolare l'accesso in tempi rapidi a diversi servizi specialistici nei reparti di Ortopedia, Chirurgia Generale, Urologia, Dermosifilopatia, Diabetologia, Oculistica, Maxillo-Facciale, Otorinolaringoiatria e Radiologia. Informati i medici di famiglia

Bienvenue dans le 21 ème épisode du podcast Corps & Esprit !

Una nuova ricerca pubblicata su Diabetologia (la rivista dell'Associazione europea per lo studio del diabete) mostra che l'attività fisica mattutina e pomeridiana è associata a un minor rischio di sviluppare il diabete di tipo 2 in tutte le fasce della popolazione. Lo studio ha coinvolto i ricercatori dell'​​Università di Harvard. Una coorte di 93.095 partecipanti (età media 62 anni) senza una storia di diabete di tipo 2 ha indossato un accelerometro che ha consentito di valutare il grado di attività fisica totale, comprese le faccende domestiche, la camminata e l'attività vigorosa. Gli autori hanno misurato i MET impiegati in tre segmenti temporali (mattina, pomeriggio e sera), divisi come 06:00-12:00 (mattina); 12:00–18:00 (pomeriggio); e 18:00–24:00 (sera).

Il 14 novembre è la Giornata Mondiale del Diabete che si celebra dal 1991, una giornata voluta dalla federazione internazionale del diabete e dall’Organizzazione Mondiale della Sanità. Conosci il tuo rischio di sviluppare il diabete di tipo2? Ne parliamo con la prof.ssa Raffaella Buzzetti, Presidente Eletto Sid, Presidente Eletto della Società Italiana di Diabetologia e Ordinario in Endocrinologia presso il Dipartimento di Medicina Sperimentale dell'Università di Roma “Sapienza” e Direttrice diabetologia all’ospedale Umberto I di Roma, ospite di Nicoletta Carbone a Obiettivo Salute risveglio.

This episode delves into what we can learn about the impact of the environment on autoimmunity, digging into how rates of autoimmunity can vary drastically in different parts of the world. ·       Intro 0:12 ·       In this episode 0:16 ·       Dr. Brian Greenwood 0:22 ·       The geography of autoimmunity 7:01 ·       Type 1 diabetes 10:31 ·       Finland and type 1 diabetes 13:57 ·       Socioeconomics 17:59 ·       Genetics and autoimmune diseases 24:19 ·       Migration studies 24:53 ·       Denmark and multiple sclerosis 30:06 ·       Coming up in part 3 36:02 ·       Thanks for listening 38:16 Disclosures: Brown reports no relevant financial disclosures. We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum. References: Bach JF. N Engl J Med. 2002;doi:10.1056/NEJMra020100. Bodansky HJ, et al. BMJ. 1992;doi:10.1136/bmj.304.6833.1020. Dean G, et al. J Neurol Neurosurg Psychiatry. 1997;doi:10.1136/jnnp.63.5.565. Hammond SR, et al. Brain. 2000;doi:10.1093/brain/123.5.968. Hawkes CH, et al. Mult Scler Relat Disord. 2019;doi:10.1016/j.msard.2019.08.001. Karvonen M, et al. Diabetes Care. 1999;doi:10.2337/diacare.22.7.1066. Kondrashova A, et al. Diabetes Care. 2007;doi:10.2337/dc06-0711. Marciulionyte D, et al. Diabetologia. 2001;doi:10.1007/s001250051574. Nielsen NM, et al. Brain. 2019;doi:10.1093/brain/awz088. Patterson CC, et al. Diabetologia. 2012;doi:10.1007/s00125-012-2571-8. Sandy JL, et al. Pediatr Diabetes. 2021;doi:10.1111/pedi.13191.

Consiglio Ue: nella notte frenata sui migranti. Ci colleghiamo con il nostro Sergio Nava, inviato a Bruxelles.Proseguono le proteste in Francia. Ci concentriamo sulla situazione integrazione delle minoranze con la prof.ssa Laura Zanfrini, sociologa delle migrazioni.Tra le buone notizie di questa settimana ce n'è una che riguarda il diabete, una ricerca che vede coinvolto anche il prof. Roberto Trevisan, professore di Endocrinologiapresso l'Università Milano-Bicocca, direttore della Diabetologia dell'ASST Papa Giovanni XXIII di Bergamo.

It's In the News, a look at the top stories and headlines from the diabetes community happening now. Top stories this week: Abbott recalls Freestyle Libre readers (not the sensors, see below for more information), Medicare expands CGM coverage for  more people with type 2, a new study looks at the transition for children with T1D to adults and why patients aren't being served well during that time, and much more! Please visit our Sponsors & Partners - they help make the show possible! Take Control with Afrezza  Omnipod - Simplify Life Learn about Dexcom  Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens  Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and these are the top diabetes stories and headlines happening now XX In the news is brought to you by Athletic Greens AG1 by Athletic Greens is daily nutrition made really simple. XX If you've got an Abbott Libre reader – check it for a huge recall. The company is issuing a class one – that's the most serious -recall of all readers distributed in the U.S. from November 2017 to February 2023, totaling more than 4 million devices. The recall is due to the potential overheating, sparking, or fire that may occur when the readers are charged with non-Abbott adapters or USB cables, or when they are damaged or exposed to liquids. Abbott-provided USB cables and power adapters limit the current to safely charge the battery, whereas third-party cables and adapters may allow much higher power, increasing the risk of fire. Abbott has reported 206 incidents related to this issue, including at least seven fires and one injury, but no deaths. I've got the phone number to call and more information in the show notes at d-c dot com. This recall only applies to those using the external reader device, not those using their smartphone. Contact Information Users with questions about this recall should contact Abbott Customer Service at 1-855-632-8658, available 7 days a week from 8AM to 8PM Eastern Time, excluding major holidays. https://www.fda.gov/medical-devices/medical-device-recalls/abbott-recalls-readers-used-freestyle-libre-freestyle-libre-14-day-and-freestyle-libre-2-flash XX A big policy change coming next week - The Centers for Medicare and Medicaid Services will expand continuous glucose monitor coverage to more people with type 2 diabetes. That starts April 16th, this Sunday if you're listening as the episode first drops. The expanded coverage applies to people using a basal only routine, as well as others who have a history of what has been classified as “problematic hypoglycemia.” Bottom line for those with type 2 – check with your doctor to see if a CGM is now covered October.https://diatribe.org/medicare-expands-cgm-continuous-glucose-monitor-coverage-type-2-diabetes XX Montana lawmakers are considering a bill that would require insurance companies to cover CGMs for people with Type 1 and Type 2 diabetes. House Bill 758 has broad support from lawmakers, but it faces opposition from insurance companies and some providers. That opposition focuses on the cost, whether a CGM is medically necessary at all stages of diabetes, and the possibility that CGM manufacturers will raise their prices if there is an insurance mandate. Blue Cross and Blue Shield of Montana, the state's largest insurer, estimates the bill, if passed, would cost the organization nearly $5 million a year. The BCBS spokesperson also says ““These things are a convenience,” https://khn.org/news/article/montana-potential-bill-insurance-covering-continuous-glucose-monitor/ XX Short-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with an increased risk for heart failure hospitalization among patients with type 2 diabetes (T2D), according to a Danish registry study. Among over 300,000 patients with T2D, short-term use of NSAIDs was associated with a relative 43% increased risk of a first-time heart failure hospitalization in the subsequent 28 days. NSAIDs increased the risk of heart failure even more in type 2 diabetics who were 80 or older (78%) or who had high blood sugar levels (68%), the results showed. Those who'd never used an NSAID before had the worst reaction, with their heart failure risk nearly tripling. However, heart failure was not associated with using NSAIDs in people with well-controlled diabetes and normal blood sugar levels. https://www.medpagetoday.com/cardiology/chf/103936 XX New study from Boston Children's Hospital shows the transition from child to young adult managing type 1 is a pretty fraught time. routine outpatient care for type 1 diabetes decreased between ages 16 and 24. At the same time, emergency room visits to treat the condition increased for that age group. The study raises the concern that young adults lack a “medical home” with an endocrinologist and instead may be seeking routine care such as insulin prescription refills from an emergency department (ED), Garvey says. If anything, the research supports the idea that endocrinologists should have an integral role in diabetes management for young adults, she says, and illustrates how specialized care may prevent the need for acute care in hospitals. The data here showed that annual endocrinologist visits declined from 2.3 per year at age 16 to 1.5 per year by age 24. This data stands out, Garvey says, because previous research has shown endocrinologists are the main providers of type 1 diabetes care for most young adults with the condition. These researchers hope the study can serve as a launching point for endocrinologists to assess how they can help young adults better manage type 1 diabetes https://answers.childrenshospital.org/self-care-of-diabetes/ XX XX The past few years have seen numerous advances in the understanding of how type 1 diabetes develops and how to manage it, yet the global disease burden remains high, according to a review article published April 5 in The Lancet. The authors cite data related to diabetes control in youth and adults from the T1D Exchange demonstrating that only 21% of adults with type 1 diabetes have an A1c (a blood test that reflects a 90-day sugar average) of 7.0 or lower. While type 1 diabetes is the third most common disease of childhood, there should be greater awareness of adult onset of the disease. The paper references data from the UK Biobank indicating that up to 40% of type 1 diabetes diagnoses occur in people over age 30. , the paper notes that racial and ethnic disparities persist and insulin pump usage is lowest at 18% among non-Latinx Black populations compared with 72% among non-Hispanic white people and 40% among Hispanic populations. The paper also reports that inhaled insulin – brand name Afrezza - has demonstrated a fast onset of action, improving the ability to control glucose after meals. https://medicalxpress.com/news/2023-04-global-diabetes-burden-high-advances.html XX A research team led by the University of Michigan Health Department of Neurology followed more than 120 patients who underwent bariatric surgery for obesity over two years after the procedure. They found that all metabolic risk factors for developing diabetes, such as high glucose and lipid levels, improved outside of blood pressure and total cholesterol, according to results published in Diabetologia. Investigators also found that patients two years removed from bariatric surgery showed improvements in peripheral neuropathy, a condition marked by damage to the nerves that go from the spinal cord all the way to the hands and feet. . Obesity is the second leading risk factor for peripheral neuropathy after diabetes, which affects more than 30 million Americans. https://medicalxpress.com/news/2023-04-bariatric-surgery-reverse-diabetes-complications.html - XX Athletic Greens XX As of April 12, 2023, Panbela Therapeutics has officially begun their Phase II double-blind, randomized study to assess the effectiveness and safety of CPP-1X-T for recent onset type 1 diabetes (T1D). The study will involve enrolling 70 patients across six different centers in the United States, with Indiana University leading the trial. The first patient has already been enrolled, which has led to a boost in the company's stock prices. Panbela Therapeutics is a clinical-stage biopharmaceutical company that specializes in developing innovative therapies for cancer patients and those with other urgent medical needs. They have recently completed a clinical trial of ivospemin, a treatment for locally advanced or metastatic pancreatic cancer. The company also acquired Cancer Prevention Pharmaceuticals in June 2022, a clinical-stage biopharmaceutical company that focuses on developing therapies to prevent cancer and rare diseases. CPP-1X-T is one of the drugs that Panbela Therapeutics is currently developing. This drug has shown potential complementary activity with the FDA-approved treatment for pancreatic cancer and is being evaluated for the treatment of T1D in the Phase II clinical trial. The company's shares have been fluctuating in recent months due to various factors, including the progress and results of their clinical trials. https://beststocks.com/panbela-therapeutics-begins-phase-ii-clinical/ XX Type 1 Diabetes Conference & Community For people living with type 1 diabetes of all ages where they can find: Information, Motivation, And Inspiration To Thrive With Type 1 Diabetes XX The book! XX On the podcast next week.. Jisel Parra was diagnosed as a teenager and it couldn't have gone worse – they didn't prescribe insulin initially, she struggled with getting the right and with her mental health.. but now she makes medical jewelry and tags with her company A Tad Too Sweet. I'm excited for you to hear her story. Last week, Dr. Bryce Nelson on Tzield. . That's In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.

Autor: Maristela Strufaldi • Ramos S, et al. Terapia Nutricional no Pré-Diabetes e no Diabetes Mellitus Tipo 2. Diretriz Oficial da Sociedade Brasileira de Diabetes (2022). Acesso em 28 de março de 2023. • Evert AB, et al. Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report. Diabetes Care. 2019 May;42(5):731-754. • Schwingshackl L, et al. A network metaanalysis on the comparative efficacy of different dietary approaches on glycaemic control in patients with type 2 diabetes mellitus. Eur J Epidemiol. 2018 Feb;33(2):157–70 • Toledo E, et al. Effect of the Mediterranean diet on blood pressure in the PREDIMED trial: results from a randomized controlled trial. BMC Med. 2013 Sep 19;11:207. • Salas-Salvadó J, et al. Effect of a Lifestyle Intervention Program With Energy-Restricted Mediterranean Diet and Exercise on Weight Loss and Cardiovascular Risk Factors: One-Year Results of the PREDIMED-Plus Trial. Diabetes Care. 2019 May;42(5):777-788. • Delgado-Lista J, et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. Lancet. 2022 May 14;399(10338):1876-1885. • Weber B, et al. Implementation of a Brazilian Cardioprotective Nutritional (BALANCE) Program for improvement on quality of diet and secondary prevention of cardiovascular events: A randomized, multicenter trial. Am Heart J. 2019 Sep;215:187-197. • Chiavaroli L, et al. DASH Dietary Pattern and Cardiometabolic Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses. Nutrients. 2019 Feb 5;11(2):338. • Freire R. Scientific evidence of diets for weight loss: Different macronutrient composition, intermittent fasting, and popular diets. Nutrition. 2020 Jan;69:110549. • Davies MJ, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022 Dec;65(12):1925-1966.

With the recent explosion in popularity of the GLP-1 agonist medications for obesity, Dr. Nally discusses a little known problem (muscle loss) becoming more significant with these drugs popularity. If you've ever considered using any of these medications in this class, you'll want to tune in to this podcast. #GLP1 #semaglutide #dulalutide #tirzepatide #liraglutide #exanatide #sarcopenia #Diet #Food #FoodIsMedicine #LeadFolloworGetOutOrMyWay #JustKeepEsterifying #Ketogenic #Keto #KetogenicLifestyle #Carnivore #DrAdamNally #DocMuscles #DocMusclesLive #DocTalk #DocsWhoLift #LiftRunShoot #DocMusclesLife #PlantBasedDietsSuck #Muscles #Cytokines #incretin #NoBSsm #Exercise References: Wilding JPH, et al. STEP 1 Study Group of the Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021; 384:989-1002. DOI: 10.1056/NEJMoa2032183. McCrimmon, R.J., Catarig, AM., Frias, J.P. et al. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia 63, 473–485 (2020). https://doi.org/10.1007/s00125-019-05065-8

Die WHO warnt seit mehr als 20 Jahren vor einem weltweiten Problem. Allein in Deutschland gelten zwei Drittel der Männer und die Hälfte der Frauen als übergewichtig oder sogar adipös. Je mehr Kilos, desto größer ist das Risiko für gravierende Folgeerkrankungen: Fettleber, Diabetes Typ 2, Krebs. Was kann die Medizin tun, wenn Abnehmen mit Ernährungsumstellung nicht gelingt? Wissenschaftsjournalistin Nele Rößler hat zu neuen Forschungsansätzen recherchiert und mit einer Betroffenen gesprochen. Im Gespräch mit Host Maja Bahtijarević erklärt sie, inwiefern Hormone der Schlüssel zu sein scheinen, welche Rolle der Grundumsatz des Körpers spielt und warum manche Adipositas-Forscher geradezu euphorisch über neue Medikamente sprechen. Die gute Nachricht: Viele Erkrankungen sind reversibel, wenn man das Gewicht in den Griff kriegt. Doch mit ein bisschen Sport allein ist es nicht getan, besonders bei Kindern. DIE HINTERGRUNDINFORMATIONEN • WHO-Stellungnahme zur Bekämpfung von Adipositas | WHO, Juni 2022 https://www.who.int/europe/de/news/item/24-06-2022-who-begins-subregional-policy-dialogues-to-fight-obesity#:~:text=Adipositas%20wird%20oft%20als%20eine,Region%20entweder%20%C3%BCbergewichtig%20oder%20adip%C3%B6s. • Sinkende Lebenserwartung in den USA| Ärzteblatt, Dezember 2019 https://www.aerzteblatt.de/blog/108208/Sinkende-Lebenserwartung-in-den-USA • Begleiterkrankungen durch Übergewicht | WHO-Report, 2000 https://pubmed.ncbi.nlm.nih.gov/11234459/ • Zusammenhang zwischen Übergewicht und Diabetes Typ 2 | Bundesärztekammer, 2021 https://www.ddg.info/fileadmin/user_upload/05_Behandlung/01_Leitlinien/Evidenzbasierte_Leitlinien/2021/diabetes-2aufl-vers1-llr.pdf • Steigendes Krebsrisiko durch Diabetes Typ 2 | Pearson-Stuttard J., Tsilidis K. et al: Type 2 Diabetes and Cancer: An Umbrella Review of Observational and Mendelian Randomization Studies. Cancer Epidemiol Biomarkers Prev 1 Juni 2021; 30 (6): 1218–1228. https://doi.org/10.1158/1055-9965.EPI-20-1245 • Warum könnte Übergewicht Krebserkrankungen begünstigen? | Schlesinger, S., Neuenschwander, M., Barbaresko, J. et al. Prediabetes and risk of mortality, diabetes-related complications and comorbidities: umbrella review of meta-analyses of prospective studies. Diabetologia 65, 275–285 (2022). https://doi.org/10.1007/s00125-021-05592-3 • Pressemitteilung des Unternehmens Eli Lilly zur Wirksamkeit des Medikaments Tirzepatid | Eli Lilly, April 2022 https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-delivered-225-weight-loss-adults-obesity-or • Wirksamkeit von Tirzepatid gegen Adipositas und Diabetes Typ 2 | Sonja Klein, Gelbe Liste, Juli 2021 https://www.gelbe-liste.de/diabetologie/tirzepatid-antidiabetikum • Studie zur Wirksamkeit von Tirzepatid | Rosenstock J., Fernández Landó L. et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial: The Lancet Juni 26 2021 https://doi.org/10.1016/S0140-6736(21)01324-6 • EMA-Zulassung für Tirzepatid | Europäische Arzneimittelagentur, November 2022 https://eur-lex.europa.eu/legal-content/DE/TXT/PDF/?uri=CELEX:52020DC0474 • Studie zur Langzeitwirkung eines Magenbypass | Adams Ted D., McKinlay R. et al. Weight and Metabolic Outcomes 12 Years after Gastric Bypass | NEJM September 21, 2017: DOI: 10.1056/NEJMoa1700459 https://pubmed.ncbi.nlm.nih.gov/28930514/ • Vergleich der Wirksamkeit einer Magenbypass-Operation und einer Magenverkleinerung | McTigue KM, Wellman R, Nauman E, et al. Comparing the 5-Year Diabetes Outcomes of Sleeve Gastrectomy and Gastric Bypass: The National Patient-Centered Clinical Research Network (PCORNet) Bariatric Study. JAMA Surg. 2020;155(5):e200087. doi:10.1001/jamasurg.2020.0087 • Monogene Formen der Adipositas | Uniklinikum Ulm, aufgerufen Januar 2023 https://www.uniklinik-ulm.de/kinder-und-jugendmedizin/sektionen-ambulanzen-und-arbeitsbereiche/sektion-paediatrische-endokrinologie-und-diabetologie/klinische-studien-und-experimentelle-forschung/experimentelle-forschung/monogene-formen-der-adipositas-leptin-und-leptinrezeptor.html • Therapie- und Folgekosten durch Diabetes Typ 2| Deutsche Diabetes-Gesellschaft, 2021 https://www.ddg.info/presse/die-diabetes-epidemie-direkte-und-indirekte-gesundheitskosten-gehen-in-die-milliarden • Vorschläge der WHO: Strategien gegen Übergewicht | WHO European Regional Obesity Report 2022 https://apps.who.int/iris/bitstream/handle/10665/353747/9789289057738-eng.pdf

Die WHO warnt seit mehr als 20 Jahren vor einem weltweiten Problem. Allein in Deutschland gelten zwei Drittel der Männer und die Hälfte der Frauen als übergewichtig oder sogar adipös. Je mehr Kilos, desto größer ist das Risiko für gravierende Folgeerkrankungen: Fettleber, Diabetes Typ 2, Krebs. Was kann die Medizin tun, wenn Abnehmen mit Ernährungsumstellung nicht gelingt? Wissenschaftsjournalistin Nele Rößler hat zu neuen Forschungsansätzen recherchiert und mit einer Betroffenen gesprochen. Im Gespräch mit Host Maja Bahtijarević erklärt sie, inwiefern Hormone der Schlüssel zu sein scheinen, welche Rolle der Grundumsatz des Körpers spielt und warum manche Adipositas-Forscher geradezu euphorisch über neue Medikamente sprechen. Die gute Nachricht: Viele Erkrankungen sind reversibel, wenn man das Gewicht in den Griff kriegt. Doch mit ein bisschen Sport allein ist es nicht getan, besonders bei Kindern. DIE HINTERGRUNDINFORMATIONEN • WHO-Stellungnahme zur Bekämpfung von Adipositas | WHO, Juni 2022 https://www.who.int/europe/de/news/item/24-06-2022-who-begins-subregional-policy-dialogues-to-fight-obesity#:~:text=Adipositas%20wird%20oft%20als%20eine,Region%20entweder%20%C3%BCbergewichtig%20oder%20adip%C3%B6s. • Sinkende Lebenserwartung in den USA| Ärzteblatt, Dezember 2019 https://www.aerzteblatt.de/blog/108208/Sinkende-Lebenserwartung-in-den-USA • Begleiterkrankungen durch Übergewicht | WHO-Report, 2000 https://pubmed.ncbi.nlm.nih.gov/11234459/ • Zusammenhang zwischen Übergewicht und Diabetes Typ 2 | Bundesärztekammer, 2021 https://www.ddg.info/fileadmin/user_upload/05_Behandlung/01_Leitlinien/Evidenzbasierte_Leitlinien/2021/diabetes-2aufl-vers1-llr.pdf • Steigendes Krebsrisiko durch Diabetes Typ 2 | Pearson-Stuttard J., Tsilidis K. et al: Type 2 Diabetes and Cancer: An Umbrella Review of Observational and Mendelian Randomization Studies. Cancer Epidemiol Biomarkers Prev 1 Juni 2021; 30 (6): 1218–1228. https://doi.org/10.1158/1055-9965.EPI-20-1245 • Warum könnte Übergewicht Krebserkrankungen begünstigen? | Schlesinger, S., Neuenschwander, M., Barbaresko, J. et al. Prediabetes and risk of mortality, diabetes-related complications and comorbidities: umbrella review of meta-analyses of prospective studies. Diabetologia 65, 275–285 (2022). https://doi.org/10.1007/s00125-021-05592-3 • Pressemitteilung des Unternehmens Eli Lilly zur Wirksamkeit des Medikaments Tirzepatid | Eli Lilly, April 2022 https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-delivered-225-weight-loss-adults-obesity-or • Wirksamkeit von Tirzepatid gegen Adipositas und Diabetes Typ 2 | Sonja Klein, Gelbe Liste, Juli 2021 https://www.gelbe-liste.de/diabetologie/tirzepatid-antidiabetikum • Studie zur Wirksamkeit von Tirzepatid | Rosenstock J., Fernández Landó L. et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial: The Lancet Juni 26 2021 https://doi.org/10.1016/S0140-6736(21)01324-6 • EMA-Zulassung für Tirzepatid | Europäische Arzneimittelagentur, November 2022 https://eur-lex.europa.eu/legal-content/DE/TXT/PDF/?uri=CELEX:52020DC0474 • Studie zur Langzeitwirkung eines Magenbypass | Adams Ted D., McKinlay R. et al. Weight and Metabolic Outcomes 12 Years after Gastric Bypass | NEJM September 21, 2017: DOI: 10.1056/NEJMoa1700459 https://pubmed.ncbi.nlm.nih.gov/28930514/ • Vergleich der Wirksamkeit einer Magenbypass-Operation und einer Magenverkleinerung | McTigue KM, Wellman R, Nauman E, et al. Comparing the 5-Year Diabetes Outcomes of Sleeve Gastrectomy and Gastric Bypass: The National Patient-Centered Clinical Research Network (PCORNet) Bariatric Study. JAMA Surg. 2020;155(5):e200087. doi:10.1001/jamasurg.2020.0087 • Monogene Formen der Adipositas | Uniklinikum Ulm, aufgerufen Januar 2023 https://www.uniklinik-ulm.de/kinder-und-jugendmedizin/sektionen-ambulanzen-und-arbeitsbereiche/sektion-paediatrische-endokrinologie-und-diabetologie/klinische-studien-und-experimentelle-forschung/experimentelle-forschung/monogene-formen-der-adipositas-leptin-und-leptinrezeptor.html • Therapie- und Folgekosten durch Diabetes Typ 2| Deutsche Diabetes-Gesellschaft, 2021 https://www.ddg.info/presse/die-diabetes-epidemie-direkte-und-indirekte-gesundheitskosten-gehen-in-die-milliarden • Vorschläge der WHO: Strategien gegen Übergewicht | WHO European Regional Obesity Report 2022 https://apps.who.int/iris/bitstream/handle/10665/353747/9789289057738-eng.pdf

Reversing chronic kidney disease (CKD) with a ketogenic lifestyle. Dr. Nally's Ketogenic Dietary Information: https://www.docmuscles.com/dietpage/ Show References: 1. Siperstein MS, Unger RH, Madison LL. “Further Electron Microscopic Studies of Diabetic Microagniopathy.” Early Diabetes: Advances in Metabolic Disorders, sup 1. New York: Academic Press, 1972, p261-271. 2. Nasr SH, D'Agati VD. “Nodular glomerulosclerosis in the nondiabetic smoker.” J Am Soc Nephrol. 2007;18(7):2032. 3. Poplawski MM, Mastaitis JW, Isoda F, Grosjean F, Zheng F, Mobbs CV (2011) Reversal of Diabetic Nephropathy by a Ketogenic Diet. PLoS ONE 6(4): e18604. doi:10.1371/journal.pone.0018604 4. Kundu S, Hossain KS, Moni A, Zahan MS, Rahman MM, Uddin MJ. Potentials of ketogenic diet against chronic kidney diseases: pharmacological insights and therapeutic prospects. Mol Biol Rep. 2022 Oct;49(10):9749-9758. doi: 10.1007/s11033-022-07460-8. Epub 2022 Apr 20. PMID: 35441940. 5. Rojas-Morales P, León-Contreras JC, Sánchez-Tapia M, Silva-Palacios A, Cano-Martínez A, González-Reyes S, Jiménez-Osorio AS, Hernández-Pando R, Osorio-Alonso H, Sánchez-Lozada LG, Tovar AR, Pedraza-Chaverri J, Tapia E. A ketogenic diet attenuates acute and chronic ischemic kidney injury and reduces markers of oxidative stress and inflammation. Life Sci. 2022 Jan 15;289:120227. doi: 10.1016/j.lfs.2021.120227. Epub 2021 Dec 16. PMID: 34921866. 6. Jolliffe N, Smith HW. The excretion of urine in the dog. I. The urea and creatinine clearances on a mixed diet. Am J Physiol 98: 572–577, 1931. 7. Parving HH, Noer J, Kehlet H, Mogensen CE, Svendsen PA, Heding L. The effect of short-term glucagon infusion on kidney function in normal man. Diabetologia 13: 323–325, 1977pmid:334617. 8. Fioretto P, Trevisan R, Velussi M, Cernigoi A, De Riva C, Bressan M, Doria A, Pauletto N, Angeli P, De Donà C, et al. Glomerular filtration rate is increased in man by the infusion of both D,L-3-hydroxybutyric acid and sodium D,L-3-hydroxybutyrate. J Clin Endocrinol Metab. 1987 Aug;65(2):331-8. doi: 10.1210/jcem-65-2-331. PMID: 3298305. #CKD #ChronicKidneyDisease #Kidney #diabeticNephropathy #Diabetes #LeadFolloworGetOutOrMyWay #JustKeepEsterifying #Ketogenic #Keto #KetogenicLifestyle #Carnivore #DrAdamNally #DocMuscles #DocMusclesLive #DocTalk #DocsWhoLift #LiftRunShoot #DocMusclesLife YouTube.com/drnally/.

VIDEOS: The Cost of Denial Clip (17:33) Hang On, Bill Gates and Dr. Fauci just did WHAT? | Redacted with Clayton Morris (21:43) There is nothing constructive about the pot calling the kettle black. – Clare Daly  (1:17) Clinical trial for nicotinamide riboside: Vitamin safely boosts levels of important cell metabolite linked to multiple health benefits University of Iowa Health Care, October 10, 2022 In a clinical trial of nicotinamide riboside (NR), a newly discovered form of Vitamin B3, researchers have shown that the compound is safe for humans and increases levels of a cell metabolite that is critical for cellular energy production and protection against stress and DNA damage. Studies in mice have shown that boosting the levels of this cell metabolite — known as NAD+ — can produce multiple health benefits, including resistance to weight gain, improved control of blood sugar and cholesterol, reduced nerve damage, and longer lifespan. Levels of NAD+ diminish with age, and it has been suggested that loss of this metabolite may play a role in age-related health decline. These findings in animal studies have spurred people to take commercially available NR supplements designed to boost NAD+. However, these over-the-counter supplements have not undergone many clinical trials to see if they work in people. The new research, reported in the journal Nature Communications, was led by Charles Brenner, PhD, professor and Roy J. Carver Chair of Biochemistry at the University of Iowa Carver College of Medicine The human trial involved six men and six women, all healthy. Each participant received single oral doses of 100 mg, 300 mg, or 1,000 mg of NR in a different sequence with a seven-day gap between doses. After each dose, blood and urine samples were collected and analyzed to measure various NAD+ metabolites in a process called metabolomics. The trial showed that the NR vitamin increased NAD+ metabolism by amounts directly related to the dose, and there were no serious side effects with any of the doses. “This trial shows that oral NR safely boosts human NAD+ metabolism,” Brenner says. “We are excited because everything we are learning from animal systems indicates that the effectiveness of NR depends on preserving and/or boosting NAD+ and related compounds in the face of metabolic stresses. Because the levels of supplementation in mice that produce beneficial effects are achievable in people, it appears than health benefits of NR will be translatable to humans safely.” Consumption of a bioactive compound from Neem plant could significantly suppress development of prostate cancer National University of Singapore, September 29, 2022 Oral administration of nimbolide, over 12 weeks shows reduction of prostate tumor size by up to 70 per cent and decrease in tumor metastasis by up to 50 per cent A team of international researchers led by Associate Professor Gautam Sethi from the Department of Pharmacology at the Yong Loo Lin School of Medicine at the National University of Singapore (NUS) has found that nimbolide, a bioactive terpenoid compound derived from Azadirachta indica or more commonly known as the neem plant or curry leaf common in throughout Indian cuisine, could reduce the size of prostate tumor by up to 70 per cent and suppress its spread or metastasis by half. In this research, we have demonstrated that nimbolide can inhibit tumor cell viability — a cellular process that directly affects the ability of a cell to proliferate, grow, divide, or repair damaged cell components — and induce programmed cell death in prostate cancer cells,” said Assoc Prof Sethi. The researchers observed that upon the 12 weeks of administering nimbolide, the size of prostate cancer tumor was reduced by as much as 70 per cent and its metastasis decreased by about 50 per cent, without exhibiting any significant adverse effects. “This is possible because a direct target of nimbolide in prostate cancer is glutathione reductase, an enzyme which is responsible for maintaining the antioxidant system that regulates the STAT3 gene in the body. The activation of the STAT3 gene has been reported to contribute to prostate tumor growth and metastasis,” explained Assoc Prof Sethi. “We have found that nimbolide can substantially inhibit STAT3 activation and thereby abrogating the growth and metastasis of prostate tumor,” he added. Mindfulness training provides a natural high, study finds University of Utah, October 20, 2022 New research from the University of Utah finds that a mindfulness meditation practice can produce a healthy altered state of consciousness in the treatment of individuals with addictive behaviors. Not unlike what one might experience under the influence of psychedelic drugs—achieving this altered state through mindful meditation has the potential lifesaving benefit of decreasing one's addictive behaviors by promoting healthy changes to the brain. The findings come from the largest neuroscience study to date on mindfulness as a treatment for addiction. The study, published in the journal Science Advances, provides new insight into the neurobiological mechanisms by which mindfulness treats addiction. Study findings provide a promising, safe and accessible treatment option for the more than 9 million Americans misusing opioids. Eric Garland is the lead author of the paper and is a distinguished professor and directs the University of Utah's Center on Mindfulness and Integrative Health Intervention Development. Garland's study builds on previous research measuring the positive effects of theta waves in the human brain. Researchers have found that individuals with low theta waves tend to experience a wandering mind, trouble concentrating or they ruminate on thoughts about themselves. Low theta waves result in a loss of self-control as the brain slips into its default mode of automatic habits. In contrast, when a person is focused, present and fully absorbed in a task, EEG scans will show increased frontal midline theta wave activity. “With high theta activity, your mind becomes very quiet, you focus less on yourself and become so deeply absorbed in what you are doing that the boundary between yourself and the thing you are focusing on starts to fade away. You lose yourself in what you are doing,” said Garland. Garland's new study showed it is in this mindful, theta wave state that people begin to experience feelings of self-transcendence and bliss, and the brain changes in ways that actually reduce one's addictive behaviors. Garland's research team recruited 165 adults with long-term opioid use for the study. Participants were randomly placed into either the control group that participated in supportive group psychotherapy or the experimental group taught to incorporate Mindfulness-Oriented Recovery Enhancement (MORE) into their daily lives. Participants showed more than twice as much frontal midline theta brain activity following treatment with MORE, whereas those in supportive therapy showed no increase in theta. Participants in MORE who showed the biggest increases in theta waves reported more intense experiences of self-transcendence during meditation, including the sense of one's ego fading away, a sense of oneness with the universe or feelings of blissful energy and love. MORE also led to significant decreases in opioid misuse through the nine-month follow-up. These reductions in opioid misuse were caused in part by the increases in frontal midline theta brain waves. Garland explained that by achieving “tastes of self-transcendence” through meditation, mindfulness therapy boosted theta waves in the frontal lobes of the brain to help participants gain self-control over their addictive behaviors. Free radicals blamed for toxic buildup in Alzheimer's brains Rutgers University, October 11, 2022. A study reported in Cell Death & Disease revealed a previously unknown mechanism that may contribute to traumatic brain injury and Alzheimer's disease. While a buildup of the protein amyloid-beta has been hypothesized to be the major driver of Alzheimer's disease, the study suggests that another protein, after undergoing oxidation by free radicals, could be a causative factor. “Indeed, scientists have known for a long time that during aging or in neurodegenerative disease cells produce free radicals,” explained lead researcher Federico Sesti, who is a professor of neuroscience and cell biology at Rutgers Robert Wood Johnson Medical School. “Free radicals are toxic molecules that can cause a reaction that results in lost electrons in important cellular components, including the channels.” Dr Sesti and colleagues determined that oxidation of a potassium channel known as KCNB1 results in a toxic buildup of this protein, leading to increased amyloid-beta production and damage to brain function. “The discovery of KCNB1's oxidation/build-up was found through observation of both mouse and human brains, which is significant as most scientific studies do not usually go beyond observing animals,” Dr Sesti reported. “Further, KCBB1 channels may not only contribute to Alzheimer's but also to other conditions of stress as it was found in a recent study that they are formed following brain trauma.” Study: Maternal, paternal exercise affects metabolic health in offspring Ohio State University, October 19, 2022 A mouse study by Kristin Stanford, with The Ohio State University College of Medicine at the Wexner Medical Center, provides new ways to determine how maternal and paternal exercise improve metabolic health of offspring. This study used mice to evaluate how their lifestyles—eating fatty foods vs. healthy and exercising vs. not—affected the metabolites of their offspring. Metabolites are substances made or used when the body breaks down food, drugs or chemicals, or its own fat or muscle tissue. This process, called metabolism, makes energy and the materials needed for growth, reproduction and maintaining health. Metabolites can serve as disease markers, particularly for type 2 diabetes and cardiovascular disease. “Tissue metabolites contribute to overall metabolism, including glucose or fatty acid metabolism, and thus systemic metabolism. We have previously shown that maternal and paternal exercise improve health of offspring. Tissue and serum metabolites play a fundamental role in the health of an organism, but how parental exercise affects offspring tissue and serum metabolites has not yet been investigated. This new data contributes to how maternal or paternal exercise could improve metabolism in offspring,” Stanford said. This study found that all forms of parental exercise improved whole-body glucose metabolism in offspring as adults, and metabolomics profiling of offspring serum, muscle, and liver reveal that parental exercise results in extensive effects across all classes of metabolites in all of these offspring tissues. Regular consumption of fried food before pregnancy increases risk of developing gestational diabetes Kennedy Shriver National Institute of Child Health and Human Development, October 10, 2022 New research published in Diabetologia (the journal of the European Association for the Study of Diabetes) shows that women who eat fried food regularly before conceiving are at increased risk of developing gestational diabetes during pregnancy. Gestational diabetes (GDM) is a complication that can arise during pregnancy, and is characterised by abnormally high blood glucose during the pregnancy (especially in the final 3 months). It can lead to increased birthweight of the child, as well jaundice and other complications. When left untreated, it can cause complications or stillbirth. Women who have GDM are more likely to later develop full blown type 2 diabetes. The authors included 21,079 singleton pregnancies from 15,027 women in the Nurses' Health Study II (NHS II) cohort. NHS II is an ongoing prospective cohort study of 116,671 female nurses in the USA aged 25-44 years at the start of study. For fried food consumption, participants were asked “how often do you eat fried food away from home (e.g. French fries, fried chicken, fried fish)?” and “how often do you eat food that is fried at home?” Both questions had four possible frequency responses: less than once per week, 1-3 times per week, 4-6 times per week, or daily. The researchers analysed fried food consumption at home and away from home separately, as well as total fried food consumption. In addition, they asked the participants what kind of frying fat/oils they usually used at home, with the possible responses as follows: real butter, margarine, vegetable oil, vegetable shortening, or lard. The association persisted after further adjustments were made for varying body-mass index (BMI). After this, the risk ratios of GDM among women who consumed total fried foods 1-3, 4-6, and 7 or more times per week, compared with those who consumed less than once per week, were 1.06, 1.14, and 1.88 respectively (thus an 88% increased risk for 7 or more times per week compared with less than once per week). The authors say: “The potential detrimental effects of fried food consumption on GDM risk may result from the modification of foods and frying medium and generation of harmful by-products during the frying process. Frying deteriorates oils through the processes of oxidation and hydrogenation, leading to an increase in the absorption of oil degradation products by the foods being fried, and also a loss of unsaturated fatty acids such as linoleic and linolenic acids and an increase in the corresponding trans fatty acids such as trans-linoleic acids and trans-linolenic acids.” They add: “Frying also results in significantly higher levels of dietary advanced glycation end products (AGEs), the derivatives of glucose-protein or glucose-lipid interactions. Recently, AGEs have been implicated in insulin resistance, pancreatic beta-cell damage, and diabetes, partly because they promote oxidative stress and inflammation. Moreover, intervention studies with a diet low in AGEs have shown significantly improved insulin sensitivity, reduced oxidant stress, and alleviated inflammation.” When analysed separately, the authors found that there was a statistically significant association of GDM with fried food consumption away from home, but not with fried food consumption at home. The authors say: “Deterioration of oils during frying is more profound when the oils are reused, a practice more common away from home than at home. This may partly explain why we observed a stronger association of GDM risk with fried foods consumed away from home than fried foods consumed at home.”

In this special podcast we will be focusing on the Consensus Report: Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).  This report was simultaneously published in Diabetologia and Diabetes Care. The report is available at:   https://diabetesjournals.org/care/article/doi/10.2337/dci22-0034/147671/Management-of-Hyperglycemia-in-Type-2-Diabetes . Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Vanita Aroda, M.D., who is a the Director of Diabetes Clinical Research at the Brigham and Women's Hospital in Boston, MA, and is an Associate Professor of Medicine at Harvard Medical School

In the second episode of our type II diabetes series, our patient Tabby joins us for a discussion on non-insulin therapies.Share your reactions and questions with us at Speak Pipe . We might feature you on a future episode!=== Outline ===IntroductionChapter 5 - Patient Centered ApproachChapter 6 - MedicationChapter 7 - ComorbiditiesChapter 8 - Barriers to medicationConclusion=== Learning Points ===There are several non-insulin medications for diabetes that can be differentiated by their mechanisms and all have different indications on when to use themA patient's comorbidities may guide your choice for starting a non-insulin therapy. Explaining the side effects of a medication in the context of its mechanism of action may go a long way in helping the patient manage expectations around new medications. Addressing mental health comorbidities such as depression and anxiety can be key to initiating and maintaining the management of diabetes.Create adestigmatizing environment when asking patients about their medication consistency=== Our Expert(s) ===Dr. Tracy Rabin is an Internist and Pediatrician who joined the Yale faculty in 2011 as a member of the Section of General Internal Medicine (YSM Department of Internal Medicine), and currently serves as the Associate Program Director for Global and Community Health in the Yale Primary Care Internal Medicine Residency Program (YPC). She attends and teaches on the medical wards at the St. Raphael's Campus (SRC) of Yale-New Haven Hospital; directs care and precepts residents in the SRC Adult Primary Care Diabetes Clinic=== References ===[American Diabetes Association] Standards of Medical Care in Diabetes—2022 Abridged for Primary Care Providers: https://diabetesjournals.org/clinical/article/40/1/10/139035/Standards-of-Medical-Care-in-Diabetes-2022  Figure depicting patient and disease factors that may be used to determine optimal HbA1C targets: Inzucchi, S.E., Bergenstal, R.M., Buse, J.B. et al. Management of hyperglycaemia in type 2 diabetes, 2015. Diabetologia 58, 429–442 (2015). https://doi.org/10.1007/s00125-014-3460-0 Herkert D, Vijayakumar P, Luo J, Schwartz JI, Rabin TL, DeFilippo E, Lipska KJ. Cost-Related Insulin Underuse Among Patients With Diabetes. JAMA Intern Med. 2019 Jan 1;179(1):112-114. doi: 10.1001/jamainternmed.2018.5008. PMID: 30508012; PMCID: PMC6583414.=== Recommended Reading ===American Diabetes Association; 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021. Diabetes Care 1 January 2021; 44 (Supplement_1): S111–S124. https://doi.org/10.2337/dc21-S009=== About Us ===The Primary Care Pearls (PCP) Podcast is created in collaboration with faculty, residents, and students from the Department of Internal Medicine at the Yale School of Medicine where give patients the autonomy to participate as experts of the lived experience of their condition.Hosts: Katie Gielissen, Maisie OrsilloPost-Production Assistant: Christina Liu, Helen CaiLogo and name: Eva ZimmermanTheme music and Editing: Josh OnyangoOther background music: Mini Vandals, Kevin MacLeod, Patrick Patrikios, Dan Bodan, Nate BlazeInstagram: @pcpearlsTwitter: @PCarePearlsListen on most podcast platforms: linktr.ee/pcpearls

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-285 Overview: Join us for a closer look at tirzepatide, a first-in-class glucose-dependent insulinotropic peptide (GIP) and a glucagon-like peptide-1 receptor agonist (GLP-1 RA). See how this novel glucose-lowering agent can help raise the bar in both HbA1c lowering and weight loss in patients with type 2 diabetes mellitus. Episode resource links: Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, Bekiari E. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022 May 17:1–11. Guest: Alan Ehrlich MD, FAAFP   Music Credit: Richard Onorato

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-285 Overview: Join us for a closer look at tirzepatide, a first-in-class glucose-dependent insulinotropic peptide (GIP) and a glucagon-like peptide-1 receptor agonist (GLP-1 RA). See how this novel glucose-lowering agent can help raise the bar in both HbA1c lowering and weight loss in patients with type 2 diabetes mellitus. Episode resource links: Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, Bekiari E. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022 May 17:1–11. Guest: Alan Ehrlich MD, FAAFP   Music Credit: Richard Onorato

Autor: Juliana de Paula Peixoto Revista: Diabetologia Ref: 'Exercise snacks' before meals: a novel strategy to improve glycaemic control in individuals with insulin resistance. Diabetologia. 2014 Jul;57(7):1437-45. doi: 10.1007/s00125-014-3244-6.

Back on the podcast, today is sleep, nutrition, and metabolism expert, Greg Potter, PhD. Through his academic research, public speaking, consulting and writing, Greg empowers people to make simple and sustainable lifestyle changes that add years to their lives and life to their years. His work has been featured in dozens of international media outlets, including Reuters, TIME, and The Washington Post, and he regularly contributes to popular websites, blogs, and podcasts. In this podcast, Greg is talking about light, including the importance of getting out in the sun and also modern problems with artificial light. He discusses the impact of light on the circadian system along with up-to-date recommendations related to light hygiene. We discuss practical tips for reducing light at night (not all of which involve putting away your device), and why not getting the right kind of light might be keeping you from achieving your body composition goals. Here's the outline of this episode with Greg Potter:  [00:02:14] Wellics Corporate Wellness Software. [00:06:49] The importance of light. [00:08:30] The introduction of electric light. [00:09:55] myLuxRecorder (Satchin Panda's app, no longer available); Podcast: How to Use Time-Restricted Eating to Reverse Disease and Optimize Health, with Satchin Panda. [00:10:37] How light influences the circadian system. [00:15:34] Consensus paper with recommendations related to light hygiene; Study: Brown, Timothy M., et al. "Recommendations for daytime, evening, and nighttime indoor light exposure to best support physiology, sleep, and wakefulness in healthy adults." PLoS biology 20.3 (2022): e3001571. [00:19:13] Practical tips for reducing light at night. [00:22:44] Increasing prevalence of myopia. [00:23:46] Podcast: Getting Stronger, with Todd Becker. [00:26:01] Vitamin D synthesis; Podcast: The Pleiotropic Effects of Sunlight, with Megan Hall. [00:26:15] Effects of light on mood and cognition. [00:27:24] Effect of light exposure patterns on cognitive performance; Study: Grant, Leilah K., et al. "Daytime exposure to short wavelength-enriched light improves cognitive performance in sleep-restricted college-aged adults." Frontiers in neurology (2021): 197. [00:28:14] Effects of light on metabolic health. [00:28:20] Dan Pardi podcast featuring Peter Light: Sunlight And Fat Metabolism: A New Discovery. [00:28:52] Effect of bright and dim light on metabolism (Netherlands); Study: Harmsen, Jan-Frieder, et al. "The influence of bright and dim light on substrate metabolism, energy expenditure and thermoregulation in insulin-resistant individuals depends on time of day." Diabetologia 65.4 (2022): 721-732. [00:30:53] Effects of light on skin and immune function. [00:31:57] Highlights #15 (topics: Sun avoidance & exposure, increasing testosterone, Robert Sapolsky). [00:35:14] Skyglow. [00:36:48] Light at night and endocrine disruption. [00:37:45] Light at night and quality/duration of sleep. [00:38:19] Blue light in the evening interferes with sleep homeostasis; Study: Cajochen, Christian, et al. "Evidence that homeostatic sleep regulation depends on ambient lighting conditions during wakefulness." Clocks & Sleep 1.4 (2019): 517-531. [00:38:53] Effects of light at night on sympathetic nervous system/cortisol; Study: Rahman, Shadab A., et al. "Characterizing the temporal dynamics of melatonin and cortisol changes in response to nocturnal light exposure." Scientific reports 9.1 (2019): 1-12. [00:39:26] Effects of light at night on heart rate, HRV, insulin resistance; Study: Mason, Ivy C., et al. "Light exposure during sleep impairs cardiometabolic function." Proceedings of the National Academy of Sciences 119.12 (2022): e2113290119. [00:41:34] Effects of moon phases on sleep; Study: Casiraghi, Leandro, et al. "Moonstruck sleep: Synchronization of human sleep with the moon cycle under field conditions." Science advances 7.5 (2021): eabe0465. [00:45:40] Effects of individual sensitivity to light; Study: Phillips, Andrew JK, et al. "High sensitivity and interindividual variability in the response of the human circadian system to evening light." Proceedings of the National Academy of Sciences 116.24 (2019): 12019-12024. [00:47:55] Camping and melatonin synthesis across seasons; Study: Stothard, Ellen R., et al. "Circadian entrainment to the natural light-dark cycle across seasons and the weekend." Current Biology 27.4 (2017): 508-513. [00:48:40] Seasonal changes in thyroid hormones (meta-analysis): Kuzmenko, N. V., et al. "Seasonal variations in levels of human thyroid-stimulating hormone and thyroid hormones: a meta-analysis." Chronobiology International 38.3 (2021): 301-317. [00:53:24] Effect of location in the world; Podcast: Morning Larks and Night Owls: the Biology of Chronotypes, with Greg Potter, PhD. [00:54:30] Daylight Savings Time transition and  traffic accidents in the US; Study: Fritz, Josef, et al. "A chronobiological evaluation of the acute effects of daylight saving time on traffic accident risk." Current biology 30.4 (2020): 729-735. [00:56:08] Effects of Daylight Savings Time on cardiac events. [00:56:48] Daylight Savings Time and cyberloafing; Study: Wagner, David T., et al. "Lost sleep and cyberloafing: Evidence from the laboratory and a daylight saving time quasi-experiment." Journal of Applied psychology 97.5 (2012): 1068.  [00:57:26] Circadian clock disrupted by Daylight Savings Time; Study: Kantermann, Thomas, et al. "The human circadian clock's seasonal adjustment is disrupted by daylight saving time." Current Biology 17.22 (2007): 1996-2000.  [01:00:44] Implications of permanent daylight savings time. [01:03:37] Effects of light at night in animals; Study: Sanders, Dirk, et al. "A meta-analysis of biological impacts of artificial light at night." Nature Ecology & Evolution 5.1 (2021): 74-81. [01:09:14] Minimizing the impact of light at night on wildlife. [01:13:50] Human-centric lighting at hospitals; Study: Giménez, Marina C., et al. "Patient room lighting influences on sleep, appraisal and mood in hospitalized people." Journal of sleep research 26.2 (2017): 236-246. [01:14:51] Babies in a neonatal unit did better with light/dark cycle; Study: Vásquez-Ruiz, Samuel, et al. "A light/dark cycle in the NICU accelerates body weight gain and shortens time to discharge in preterm infants." Early human development 90.9 (2014): 535-540. [01:17:59] Effects of light at night on plants; Study: Ffrench-Constant, Richard H., et al. "Light pollution is associated with earlier tree budburst across the United Kingdom." Proceedings of the Royal Society B: Biological Sciences 283.1833 (2016): 20160813. [01:18:50] Maturation of soybeans shifted with  artificial light at night; Study: Palmer, Matthew, et al. Roadway lighting's impact on altering soybean growth. No. FHWA-ICT-17-010. 2017. [01:19:44] How to optimise your light environment. [01:19:54] Incandescent vs compact fluorescent bulbs. [01:21:58] LED lights. [01:25:33] Light-emitting devices with screens; metamerism. [01:26:20] Using metamerism to regulate impact of digital devices; Study: Allen, Annette E., et al. "Exploiting metamerism to regulate the impact of a visual display on alertness and melatonin suppression independent of visual appearance." Sleep 41.8 (2018): zsy100. [01:26:51] Software that reduces your exposure to short wavelengths: Nightshift (iPhone), Night Light/Blue Light Filter (Android), f.lux. [01:27:23] Apps to prevent short-wavelength light emissions do help; Study: Gringras, Paul, et al. "Bigger, brighter, bluer-better? Current light-emitting devices–adverse sleep properties and preventative strategies." Frontiers in public health 3 (2015): 233. [01:27:31] Blue-light blocking app did not improve sleep; Study: Smidt, Alec M., et al. "Effects of Automated Diurnal Variation in Electronic Screen Temperature on Sleep Quality in Young Adults: A Randomized Controlled Trial." Behavioral Sleep Medicine (2021): 1-17. [01:28:31] Blue-blockers. [01:31:31] Recommendations for shift workers. Greg's paper on this topic: Potter, Gregory DM, and Thomas R. Wood. "The future of shift work: Circadian biology meets personalised medicine and behavioural science." Frontiers in Nutrition 7 (2020): 116. [01:33:34] Jet lag: Jet Lag Rooster. [01:37:27] Find Greg on Instagram, TikTok; gregpotterphd.com [01:37:56] Book: When Brains Dream: Understanding the Science and Mystery of Our Dreaming Minds, by Antonio Zadra. [01:38:08] Book: The Beginning of Infinity: Explanations That Transform the World, by David Deutsch. [01:38:32] Book: The Precipice by Toby Ord.

Dr William Davis is an interventional cardiologist with the purpose of preventing and reversing coronary disease which has taken him on a journey to become a master educator, investigator and author.. After 25 years of practicing cardiology, he became disillusioned with the medical system's narrow focus on prescription drugs and surgical procedures. Dr Davis then began to look at natural, logical and inexpensive solutions with great success, leading him to becoming a multiple New York Times best selling author, selling over 4 million books including “Wheat Belly” and his latest  “Super Gut”, which details his unique 4 week plan to reprogram your microbiome and restore your health. JOIN US AS WE EXPLORE:A gut microbiome masterclass! From symbiosis, eubiosis, dysbiosis, SIBO, probiotics and moreWhat has wrecked such enormous devastating on everyone's gut in the modern world Dr Davis's favorite bacteria! Why food intolerances are not about the food but about YOU and your gut!A game changing biohacking device for your gut healthEndotoxaemia and it's relation to diseases from fibromyalgia to ALS and depression The incredible world of fermenting and creating personalized, disease-specific probioticsCONTACT:Website – https://drdavisinfinitehealth.comWebsite - https://www.undoctored.comMENTIONS:  Product – AIRE, https://foodmarble.com/what-is-it/Study - Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, Gibson GR, Delzenne NM. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007 Nov;50(11):2374-83. doi: 10.1007/s00125-007-0791-0. Epub 2007 Sep 6. PMID: 17823788.Study - Chedid, V., Dhalla, S., Clarke, J. O., Roland, B. C., Dunbar, K. B., Koh, J., Justino, E., Tomakin, E., & Mullin, G. E. (2014). Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth. Global advances in health and medicine, 3(3), 16–24. https://doi.org/10.7453/gahmj.2014.019Product – Sugar Shift, https://biotiquest.com/pages/sugar-shiftProduct – Synbiotic365, https://www.unitednaturals.com/products/synbiotic-365-advanced-probiotic-formula

Description: A year ago, we published an episode looking at diabetes management in the context of ongoing restrictions in many parts of the world. Since then, a wealth of clinical data has continued to be published on the bidirectional relationship between diabetes and Covid-19, so today we're taking a closer look at these data. We're joined by Professor Partha Kar, National Specialty Advisor, Diabetes for NHS England, to discuss what the data mean for clinical practice. By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources. References: Kamrath C, et al. Incidence of Type 1 Diabetes in Children and Adolescents During the COVID-19 Pandemic in Germany: Results From the DPV Registry. Diabetes Care. 2022 Jan 17:dc210969. Gottesman BL, et al. Incidence of New-Onset Type 1 Diabetes Among US Children During the COVID-19 Global Pandemic. JAMA Pediatr. 2022 Apr 1;176(4):414-415. McGlacken-Byrne SM, et al. The SARS-CoV-2 pandemic is associated with increased severity of presentation of childhood onset type 1 diabetes mellitus: A multi-centre study of the first COVID-19 wave. Diabet Med. Sep 2021;38(9):e14640. Barrett CE, et al. Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged

New study reveals that healthy plant-based diets are associated with a lower risk of developing diabetes   Harvard School of Public Health, April 8, 2022   New research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]) finds that the consumption of healthy plant-based foods, including fruits, vegetables, nuts, coffee, and legumes, is associated with a lower risk of developing type 2 diabetes (T2D) in generally healthy people and support their role in diabetes prevention. The study aimed to identify the metabolite profiles related to different plant-based diets and investigate possible associations between those profiles and the risk of developing T2D.   (NEXT)   Vitamin K2 brain benefit   Al-Maarefa University (Saudi Arabia), April 8 2022.    Results from a study  suggest that vitamin K2 could help protect the brain from aging-associated disorders. The study's investigators remarked that people with severe dementia and individuals at an early stage of Alzheimer's disease have an increased risk of reduced serum vitamin K levels. Rats that received vitamin K2 had less cognitive impairment, depression and anxiety, and better spatial memory and learning ability compared to untreated animals. When the two groups' maze performances at the end of the treatment period were compared with untreated young adult rats, older animals that received MK-7 performed similarly to the younger rats, while the performance of older untreated rats was significantly lower.   (NEXT)   Research finds that wisdom is a matter of both heart and mind   University of Waterloo (Canada) April 7, 2022    The fluctuations of your heartbeat may affect your wisdom, according to new research from the University of Waterloo. The study suggests that heart rate variation and thinking process work together to enable wise reasoning about complex social issues. "Our research shows that wise reasoning is not exclusively a function of the mind and cognitive ability," says Prof. Grossmann. "We found that people who have greater heart rate variability and who are able to think about social problems from a distanced viewpoint demonstrate a greater capacity for wise reasoning." A growing consensus among philosophers and cognitive scientists defines wise judgment to include the ability to recognize the limits of one's knowledge, to be aware of the varied contexts of life and how they may unfold over time, to acknowledge others' points of view, and to seek reconciliation of opposing viewpoints.   (NEXT)   Too much sitting may shorten your life, study suggests   University of Sao Paulo School of Medicine April 7, 2022    A new study finds that sitting less may extend your life. Brazilian researchers who analyzed data from 54 countries linked sitting for more than three hours a day to 3.8 percent of deaths from all causes. Limiting sitting time to less than three hours a day would increase a person's life expectancy by an average of 0.2 years—or more than two months, the researchers said. The study authors estimated the effects of less time spent sitting, regardless of moderate to vigorous physical activity. Even a modest, 10 percent reduction in sitting time—for instance, 30 fewer minutes a day—could have an immediate impact, the researchers said.   (NEXT)   Depressive disorders can lead to changes in immune cells   Dresden University of Technology and University of Zurich (Germany), April 9.2022   Loss of interest, joylessness, lack of drive and increased fatigability—all these complaints are among the main symptoms of depression, a mental illness affecting an estimated 5% of the population in Germany. Pathophysiological features of depressive disorders often include low-grade inflammation and elevated glucocorticoid output. In a new study published in the journal Translational Psychiatry, researchers establish for the first time a link between depressive disorders and mechanical changes in blood cells.  Videos: https://rumble.com/vwl1gx-ukrainian-soldiers-are-bombing-ukrainian-civilians.html 1. WEF Lead Advisor Yuval Noah Harari 3 “Digital Programmable Money”. Economist at World Government Summit Says New Financial World Order About to Shift in Dramatic New Direction 5. LOUISIANA NURSE: “WE HAVE HAD MORE CHILDREN DIE FROM THE COVID VACCINE THAN OF COVID ITSELF"  

L'apertura della bufala in tavola è dedicata al rapporto che abbiamo con il cibo. Ne parliamo con il dottor Stefano Erzegovesi, Direttore del centro disturbi alimentari dell'ospedale San Raffaele di Milano. Ipertensione e alimentazioni quali cibi scegliere? Ne parliamo con il prof. Lelio Morricone, responsabile del servizio di Nutrizione clinica e prevenzione cardiometabolica e del Servizio di Diabetologia e Malattie metaboliche all'Istituto Clinico Sant' Ambrogio di Milano e la prof.ssa Silvana Hrelia, docente di biochimica della nutrizione dipartimento di scienze per la qualità della vita all'Università di Bologna. In chiusura per la rubrica "aggiungi un posto a tavola" ospitiamo Anna Gerasi recente vincitrice della finale italiana del World Chocolate Masters.

Alla tavola della bufala in tavola parliamo di metabolismo, alimentazione e attività sportiva. Intervengono il prof. Antonio Paoli, professore di scienze dell'esercizio fisico all'Università di Padova e il dottor Massimo Gualerzi, cardiologo ed esperto in riabilitazione cardio-metabolica Con il prof. Lelio Morricone, responsabile del servizio di Nutrizione clinica e prevenzione cardiometabolica e del Servizio di Diabetologia e Malattie metaboliche all’Istituto Clinico Sant’ Ambrogio di Milano, parliamo di glicemia. Come tenerla sotto controllo? La parola all’esperta In chiusura per la rubrica “Aggiungi un posto a tavola” Mario Caironi ricercatore dell'Istituto Italiano di Tecnologia che con il suo team ha realizzato il transistor più sottile mai esistito. Con l’esperto parliamo di come “alimentare” la creatività e la ricerca

Conto alla rovescia per il festival della canzone italiana. Come ci prepara dal punto di vista alimentare a questo appuntamento? Alla tavola della bufala della tavola ne parliamo con il dottor Attilio Speciani, medico allergologo e immunologo a Milano e la nostra Marta Cagnola Con il dottor Iader Fabbri, biologo nutrizionista e autore di Ricette vegane e vegetariane anche per onnivori (Mondadori), cerchiamo di capire cosa portare in tavola per accontentare tutti i gusti La puntata prosegue con il prof. Lelio Morricone, responsabile del servizio di Nutrizione clinica e prevenzione cardiometabolica e del Servizio di Diabetologia e Malattie metaboliche all Istituto Clinico Sant’ Ambrogio di Milano, parliamo di colesterolo e di come tenerlo sotto controllo In chiusura per la rubrica “aggiungi un posto a tavola” torna a trovarci Marina Marazza, scrittrice e storica, per parlare del piatto preferito di Paganini

Che cosa significa portare la gentilezza a tavola? Ne parliamo con il prof. Enzo Spinsi, professore associato e dirige il Laboratorio di Fisiologia Traslazionale e Nutrizione del Dipartimento di Scienze Biologiche, Geologiche ed Ambientali dell'Università di Bologna e autore dei “MAGNIFICI 20 PER LE TUE DIFESE” e Daniel Lumera, riferimento internazionale del benessere, e della pratica della meditazione Giornata Mondiale del diabete: in puro stile bufala in tavola cerchiamo di capire e di farci raccontare dai nostri esperti quanto uno stile di vita sano giochi un ruolo decisamente importante in questa patologia. Ma non solo nel corso della puntata scopriremo o meglio smaschereremo anche alcune bufale che riguardano proprio il diabete. Ne parliamo con il dottor Federico Bertuzzi, Responsabile della Diabetologia di Niguarda e il dottor Stefano Erzegovesi, Direttore del centro disturbi alimentari dell'ospedale San Raffaele di Milano